Action APM APTORUM GROUP LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Aptorum Group Limited

Actions

APM

KYG6096M1226

Temps réel estimé Cboe BZX
Autres places de cotation
 20:54:26 29/04/2024 		Varia. 5j. Varia. 1 janv.
4,93 USD -6,63 % Graphique intraday de Aptorum Group Limited -11,84 % +103,79 %
06/03 Les plus fortes hausses de la mi-journée MT
29/01 Les plus mauvais élèves du prémarché MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Top Midday Gainers
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.
Top Premarket Decliners
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
Aptorum Group Limited Announces Chief Executive Changes
Aptorum Group Limited Announces Management Changes
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
Aptorum : Securities Purchase Agreement - Form 6-K
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation
Top Premarket Decliners
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
Top Premarket Gainers
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development
Aptorum Group Limited announced that it has received $3 million in funding
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action APM
  4. Actualités Aptorum Group Limited
  5. Autres langues